JPWO2015037655A1 - Agents for reducing protein catabolism or promoting anabolism - Google Patents
Agents for reducing protein catabolism or promoting anabolism Download PDFInfo
- Publication number
- JPWO2015037655A1 JPWO2015037655A1 JP2015536619A JP2015536619A JPWO2015037655A1 JP WO2015037655 A1 JPWO2015037655 A1 JP WO2015037655A1 JP 2015536619 A JP2015536619 A JP 2015536619A JP 2015536619 A JP2015536619 A JP 2015536619A JP WO2015037655 A1 JPWO2015037655 A1 JP WO2015037655A1
- Authority
- JP
- Japan
- Prior art keywords
- amount
- agent
- protein
- catabolism
- kcal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 68
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 68
- 230000015556 catabolic process Effects 0.000 title claims abstract description 50
- 230000015572 biosynthetic process Effects 0.000 title claims abstract description 32
- 230000001737 promoting effect Effects 0.000 title claims abstract description 30
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 94
- 238000000502 dialysis Methods 0.000 claims abstract description 24
- 239000011734 sodium Substances 0.000 claims abstract description 20
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract description 19
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims abstract description 19
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims abstract description 19
- 239000011574 phosphorus Substances 0.000 claims abstract description 19
- 229910052698 phosphorus Inorganic materials 0.000 claims abstract description 19
- 239000011591 potassium Substances 0.000 claims abstract description 19
- 229910052700 potassium Inorganic materials 0.000 claims abstract description 19
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 19
- 150000002632 lipids Chemical class 0.000 claims abstract description 16
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 7
- 239000011707 mineral Substances 0.000 claims abstract description 7
- 235000021056 liquid food Nutrition 0.000 claims abstract description 5
- 150000001413 amino acids Chemical class 0.000 claims description 36
- 239000008280 blood Substances 0.000 claims description 35
- 210000004369 blood Anatomy 0.000 claims description 35
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 17
- 239000011575 calcium Substances 0.000 claims description 10
- 239000011777 magnesium Substances 0.000 claims description 10
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 9
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 9
- 229930003316 Vitamin D Natural products 0.000 claims description 9
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 9
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 9
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 9
- 229910052791 calcium Inorganic materials 0.000 claims description 9
- 229910052749 magnesium Inorganic materials 0.000 claims description 9
- 235000019166 vitamin D Nutrition 0.000 claims description 9
- 239000011710 vitamin D Substances 0.000 claims description 9
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 9
- 229940046008 vitamin d Drugs 0.000 claims description 9
- 239000011701 zinc Substances 0.000 claims description 9
- 229910052725 zinc Inorganic materials 0.000 claims description 9
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 8
- 229910052742 iron Inorganic materials 0.000 claims description 8
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 7
- 230000009467 reduction Effects 0.000 claims description 7
- 229940088594 vitamin Drugs 0.000 claims description 7
- 229930003231 vitamin Natural products 0.000 claims description 7
- 235000013343 vitamin Nutrition 0.000 claims description 7
- 239000011782 vitamin Substances 0.000 claims description 7
- 235000019155 vitamin A Nutrition 0.000 claims description 7
- 239000011719 vitamin A Substances 0.000 claims description 7
- 229940045997 vitamin a Drugs 0.000 claims description 7
- 235000014633 carbohydrates Nutrition 0.000 abstract description 11
- 210000003205 muscle Anatomy 0.000 abstract description 9
- 208000030212 nutrition disease Diseases 0.000 abstract description 5
- 208000019180 nutritional disease Diseases 0.000 abstract description 4
- 235000000346 sugar Nutrition 0.000 abstract description 3
- 150000008163 sugars Chemical class 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 58
- 150000005693 branched-chain amino acids Chemical class 0.000 description 11
- 238000000034 method Methods 0.000 description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 208000001647 Renal Insufficiency Diseases 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 201000006370 kidney failure Diseases 0.000 description 7
- 235000016709 nutrition Nutrition 0.000 description 7
- 230000003907 kidney function Effects 0.000 description 6
- 238000005259 measurement Methods 0.000 description 5
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 4
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 4
- 229930003451 Vitamin B1 Natural products 0.000 description 4
- 229930003471 Vitamin B2 Natural products 0.000 description 4
- 229930003268 Vitamin C Natural products 0.000 description 4
- 229930003427 Vitamin E Natural products 0.000 description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 229960002477 riboflavin Drugs 0.000 description 4
- 229960003495 thiamine Drugs 0.000 description 4
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 4
- 235000010374 vitamin B1 Nutrition 0.000 description 4
- 239000011691 vitamin B1 Substances 0.000 description 4
- 235000019164 vitamin B2 Nutrition 0.000 description 4
- 239000011716 vitamin B2 Substances 0.000 description 4
- 235000019154 vitamin C Nutrition 0.000 description 4
- 239000011718 vitamin C Substances 0.000 description 4
- 235000019165 vitamin E Nutrition 0.000 description 4
- 239000011709 vitamin E Substances 0.000 description 4
- 229940046009 vitamin E Drugs 0.000 description 4
- 208000002720 Malnutrition Diseases 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 230000001071 malnutrition Effects 0.000 description 3
- 235000000824 malnutrition Nutrition 0.000 description 3
- 208000015380 nutritional deficiency disease Diseases 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 102000008934 Muscle Proteins Human genes 0.000 description 2
- 108010074084 Muscle Proteins Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 235000021152 breakfast Nutrition 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 1
- PVXPPJIGRGXGCY-DJHAAKORSA-N 6-O-alpha-D-glucopyranosyl-alpha-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@](O)(CO)O1 PVXPPJIGRGXGCY-DJHAAKORSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 208000029578 Muscle disease Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- -1 medium chain fatty acid triglycerides Chemical class 0.000 description 1
- 150000004667 medium chain fatty acids Chemical class 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 235000021075 protein intake Nutrition 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
人体におけるタンパク質の異化の軽減または同化の促進によって、透析患者などの栄養障害またはその可能性のある者における筋肉の減少を抑制または予防することができる剤を提供する。エネルギー100kcal当たり、タンパク質の量が0.5〜5g、リンの量が10〜50mg、ナトリウムの量が10〜100mg、カリウムの量が5〜50mgである、タンパク質の異化軽減または同化促進のための剤。該剤は、さらに、脂質、糖質、ミネラルおよび水を含むことができ、流動食として摂取可能である。この場合、エネルギー100kcal当たり、脂質の量は、1〜5g、糖質の量は、10〜20gであり、かつ、1ミリリットル当たりのエネルギーは、1〜2kcalである。Provided is an agent capable of suppressing or preventing muscle loss in a nutritional disorder such as a dialysis patient or a person with such possibility by reducing protein catabolism or promoting assimilation in a human body. The amount of protein is 0.5 to 5 g per 100 kcal of energy, the amount of phosphorus is 10 to 50 mg, the amount of sodium is 10 to 100 mg, and the amount of potassium is 5 to 50 mg for reducing catabolism or promoting anabolism Agent. The agent can further contain lipids, sugars, minerals and water, and can be taken as a liquid food. In this case, per 100 kcal of energy, the amount of lipid is 1 to 5 g, the amount of carbohydrate is 10 to 20 g, and the energy per milliliter is 1 to 2 kcal.
Description
本発明は、タンパク質の異化軽減または同化促進のための剤に関する。 The present invention relates to an agent for reducing protein catabolism or promoting anabolism.
腎臓病の治療のために人工透析療法を受けている患者(以下、透析患者という。)にとって、蛋白・エネルギー栄養障害(PEW;protein−energy wasting)が起きているか否かは、重要な問題である。
ここで、蛋白・エネルギー栄養障害(PEW)とは、タンパク質およびエネルギーが不足する状態をいう。蛋白・エネルギー栄養障害(PEW)は、骨格筋や血清などにおけるタンパク質の減少を伴うものであって、手術後や病気の発症後の患者の状態を把握するための重要な因子である。
透析患者における蛋白・エネルギー栄養障害(PEW)などの原因として、食欲の低下によるタンパク質の摂取の不足およびエネルギーの不足や、人工透析療法におけるアミノ酸およびタンパク質の喪失(透析液中への排出)や、筋タンパク質の異化(分解)亢進、骨格筋などの炎症等が挙げられる。It is an important issue for patients undergoing artificial dialysis for the treatment of kidney disease (hereinafter referred to as dialysis patients) whether or not protein-energy nutrition disorder (PEW) has occurred. is there.
Here, protein / energy malnutrition (PEW) refers to a state where protein and energy are deficient. Protein and energy malnutrition (PEW) is accompanied by a decrease in protein in skeletal muscle, serum, and the like, and is an important factor for grasping a patient's condition after surgery or after onset of illness.
Causes of protein and energy malnutrition (PEW) in dialysis patients include insufficiency of protein intake and energy due to decreased appetite, loss of amino acids and proteins in artificial dialysis therapy (excretion into dialysate), Examples include increased catabolism (degradation) of muscle proteins and inflammation of skeletal muscles.
筋タンパク質の異化(分解)の軽減または同化(生成)の促進は、筋肉の減少による体力の消耗を抑制する点で、タンパク質や水分などの摂取量を制限されている透析患者などの病人にとって、有益である。
従来、タンパク質の異化の軽減などのための種々の方法が知られている。
例えば、特許文献1に、インスリン抵抗性を患う対象の処置の為の医薬の製造において、タンパク性物質を含む組成物を使用する方法であって、該タンパク性物質が該組成物のエネルギー値の少なくとも24.0%を与え、かつ、タンパク性物質に基づき少なくとも12重量%のロイシンを与える、上記方法が記載されている。Reduction of muscle protein catabolism (degradation) or promotion of assimilation (generation) reduces the exhaustion of physical strength due to muscle loss, for dialysis patients such as dialysis patients who have limited intake of protein and water, It is beneficial.
Conventionally, various methods for reducing protein catabolism are known.
For example, Patent Document 1 discloses a method of using a composition containing a proteinaceous substance in the manufacture of a medicament for treating a subject suffering from insulin resistance, wherein the proteinaceous substance has an energy value of the composition. The above method is described which provides at least 24.0% and at least 12% by weight of leucine based on proteinaceous material.
また、特許文献2に、個体における筋肉損失を治療する方法であって、分岐鎖アミノ酸(BCAA)、BCAA前駆体、BCAA代謝物、BCAAリッチタンパク質、またはBCAA含量が増加するように操作されたタンパク質、の少なくとも1種の有効量を個体に投与するステップを含み、BCAA、BCAA前駆体、BCAA代謝物、BCAAリッチタンパク質、およびBCAA含量が増加するように操作されたタンパク質、の少なくとも1種がタンパク質の異化に拮抗する方法が記載されている。
さらに、特許文献3に、動物における激しい身体活動からの回復に影響を及ぼすのに適した組成物であって、約4%〜6%の容易に吸収可能な炭水化物、約10%〜30%のマルトデキストリン、および約20%〜50%のデンプン、合計で約40%〜80%の炭水化物、並びに約20%〜約40%のタンパク質を含む組成物が記載されている。Patent Document 2 discloses a method for treating muscle loss in an individual, wherein the branched chain amino acid (BCAA), BCAA precursor, BCAA metabolite, BCAA-rich protein, or protein manipulated to increase BCAA content. At least one of the following: administering to the individual at least one effective amount of: BCAA, BCAA precursor, BCAA metabolite, BCAA-rich protein, and protein engineered to increase BCAA content A method for antagonizing catabolism is described.
In addition, US Pat. No. 6,057,049 is a composition suitable for affecting recovery from intense physical activity in animals, comprising about 4% to 6% easily absorbable carbohydrates, about 10% to 30%. A composition comprising maltodextrin and about 20% to 50% starch, a total of about 40% to 80% carbohydrate, and about 20% to about 40% protein is described.
上述の特許文献1〜3に記載された技術は、いずれも、人体を対象にした試験によって、その効果が実証されたものではない。
本発明は、人体におけるタンパク質の異化の軽減または同化の促進によって、透析患者などの栄養障害またはその可能性のある者における筋肉の減少を抑制または予防することができる剤を提供することを目的とする。None of the techniques described in Patent Documents 1 to 3 described above have proved their effects by tests on the human body.
An object of the present invention is to provide an agent capable of suppressing or preventing muscle loss in a person having or possibly having a nutritional disorder such as a dialysis patient by reducing protein catabolism or promoting anabolism in the human body. To do.
本発明者は、上記課題を解決するために鋭意検討した結果、エネルギー100kcal当たり、タンパク質の量が0.5〜5g、リンの量が10〜50mg、ナトリウムの量が10〜100mg、カリウムの量が5〜50mgである剤によれば、人体におけるタンパク質の異化の軽減または同化の促進の作用が発揮され、筋肉の減少による体力の消耗を抑制または予防しうることを見出し、本発明を完成した。 As a result of intensive studies to solve the above problems, the present inventors have found that the amount of protein is 0.5 to 5 g, the amount of phosphorus is 10 to 50 mg, the amount of sodium is 10 to 100 mg, and the amount of potassium per 100 kcal of energy. The present invention has been found that an agent of 5 to 50 mg can reduce protein catabolism or promote anabolism in the human body, and can suppress or prevent exhaustion of physical strength due to muscle loss. .
本発明は、以下の[1]〜[12]を提供するものである。
[1] エネルギー100kcal当たり、タンパク質の量が0.5〜5g、リンの量が10〜50mg、ナトリウムの量が10〜100mg、カリウムの量が5〜50mgであることを特徴とするタンパク質の異化軽減または同化促進のための剤。
[2] タンパク質、脂質、糖質、ミネラルおよび水を含む、流動食として摂取可能なタンパク質の異化軽減または同化促進のための剤であって、エネルギー100kcal当たり、タンパク質の量が0.5〜5g、脂質の量が1〜5g、糖質の量が10〜20g、リンの量が10〜50mg、ナトリウムの量が10〜100mg、カリウムの量が5〜50mgであり、1ミリリットル当たりのエネルギーが1〜2kcalであることを特徴とするタンパク質の異化軽減または同化促進のための剤。
[3] ビタミンを含み、かつ、エネルギー100kcal当たり、カルシウムの量が10〜50mg、マグネシウムの量が5〜30mg、鉄の量が0.2〜2mg、亜鉛の量が0.2〜2mg、ビタミンAの量が10〜100μgRE、ビタミンDの量が0.1〜0.5μgである、上記[1]または[2]に記載のタンパク質の異化軽減または同化促進のための剤。
[4] 1回投与分の容量が、100〜300ミリリットルである、上記[1]〜[3]のいずれか1項に記載のタンパク質の異化軽減または同化促進のための剤。
[5] 透析患者に用いるための、上記[1]〜[4]のいずれかに記載のタンパク質の異化軽減または同化促進のための剤。The present invention provides the following [1] to [12].
[1] Protein catabolism characterized in that the amount of protein is 0.5 to 5 g, the amount of phosphorus is 10 to 50 mg, the amount of sodium is 10 to 100 mg, and the amount of potassium is 5 to 50 mg per 100 kcal of energy. Agents for reducing or promoting anabolism.
[2] An agent for reducing catabolism or promoting anabolism of protein that can be ingested as a liquid food, including protein, lipid, sugar, mineral and water, and the amount of protein is 0.5 to 5 g per 100 kcal of energy. The amount of lipid is 1 to 5 g, the amount of carbohydrate is 10 to 20 g, the amount of phosphorus is 10 to 50 mg, the amount of sodium is 10 to 100 mg, the amount of potassium is 5 to 50 mg, and the energy per milliliter is An agent for reducing catabolism or promoting anabolism of a protein, characterized by being 1 to 2 kcal.
[3] Contains vitamins, and per 100 kcal of energy, the amount of calcium is 10 to 50 mg, the amount of magnesium is 5 to 30 mg, the amount of iron is 0.2 to 2 mg, the amount of zinc is 0.2 to 2 mg, vitamins The agent for reducing catabolism or promoting anabolism according to the above [1] or [2], wherein the amount of A is 10 to 100 μg RE and the amount of vitamin D is 0.1 to 0.5 μg.
[4] The agent for reducing catabolism or promoting anabolism according to any one of [1] to [3] above, wherein the volume of one dose is 100 to 300 ml.
[5] The agent for reducing catabolism or promoting anabolism of the protein according to any one of [1] to [4] for use in a dialysis patient.
[6] 上記タンパク質の異化軽減または同化促進のための剤は、該剤の摂取時から3時間後の動脈血中のアミノ酸濃度の値から、非摂取状態における動脈血中のアミノ酸濃度の値を差し引いて得られる値が、0以上になる者に経口投与するためのものである、上記[1]〜[5]のいずれかに記載のタンパク質の異化軽減または同化促進のための剤。
[7] エネルギー100kcal当たり、タンパク質の量が0.5〜5g、リンの量が10〜50mg、ナトリウムの量が10〜100mg、カリウムの量が5〜50mgである剤の、タンパク質の異化軽減または同化促進のための使用。
[8] タンパク質、脂質、糖質、ミネラルおよび水を含む、流動食として摂取可能な剤であって、エネルギー100kcal当たり、タンパク質の量が0.5〜5g、脂質の量が1〜5g、糖質の量が10〜20g、リンの量が10〜50mg、ナトリウムの量が10〜100mg、カリウムの量が5〜50mgであり、1ミリリットル当たりのエネルギーが1〜2kcalである剤の、タンパク質の異化軽減または同化促進のための使用。
[9] ビタミンを含み、かつ、エネルギー100kcal当たり、カルシウムの量が10〜50mg、マグネシウムの量が5〜30mg、鉄の量が0.2〜2mg、亜鉛の量が0.2〜2mg、ビタミンAの量が10〜100μgRE、ビタミンDの量が0.1〜0.5μgである上記[7]または[8]に記載の剤の、タンパク質の異化軽減または同化促進のための使用。
[10] 1回投与分の容量が、100〜300ミリリットルである、上記[7]〜[9]のいずれかに記載の剤の使用。
[11] 透析患者のための、上記[7]〜[10]のいずれかに記載の剤の使用。
[12] 上記剤の使用は、該剤の摂取時から3時間後の動脈血中のアミノ酸濃度の値から、非摂取状態における動脈血中のアミノ酸濃度の値を差し引いて得られる値が、0以上になる者に経口投与するための使用である、上記[7]〜[11]のいずれかに記載の剤の使用。[6] The agent for reducing protein catabolism or promoting anabolism is obtained by subtracting the value of amino acid concentration in arterial blood in a non-ingested state from the value of amino acid concentration in arterial blood 3 hours after the intake of the agent. The agent for reducing catabolism or promoting anabolism according to any one of the above [1] to [5], wherein the obtained value is for oral administration to those who become 0 or more.
[7] Reduction of protein catabolism of an agent having an amount of protein of 0.5 to 5 g, an amount of phosphorus of 10 to 50 mg, an amount of sodium of 10 to 100 mg, and an amount of potassium of 5 to 50 mg per 100 kcal of energy Use to promote assimilation.
[8] An agent that can be ingested as a liquid food containing protein, lipid, carbohydrate, mineral and water, and the amount of protein is 0.5 to 5 g, the amount of lipid is 1 to 5 g, and sugar per 100 kcal of energy. The amount of protein is 10 to 20 g, the amount of phosphorus is 10 to 50 mg, the amount of sodium is 10 to 100 mg, the amount of potassium is 5 to 50 mg and the energy per milliliter is 1 to 2 kcal. Use to reduce catabolism or promote anabolism.
[9] Contains vitamins, and per 100 kcal of energy, the amount of calcium is 10 to 50 mg, the amount of magnesium is 5 to 30 mg, the amount of iron is 0.2 to 2 mg, the amount of zinc is 0.2 to 2 mg, vitamins Use of the agent according to the above [7] or [8], wherein the amount of A is 10 to 100 μg RE and the amount of vitamin D is 0.1 to 0.5 μg for reducing catabolism or promoting anabolism.
[10] Use of the agent according to any one of [7] to [9] above, wherein the volume of one dose is 100 to 300 ml.
[11] Use of the agent according to any one of [7] to [10] above for dialysis patients.
[12] The use of the above agent is such that the value obtained by subtracting the value of the amino acid concentration in arterial blood in a non-ingested state from the value of the amino acid concentration in arterial blood 3 hours after the intake of the agent is 0 or more. Use of the agent according to any one of [7] to [11] above, wherein the agent is used for oral administration to an adult.
本発明のタンパク質の異化軽減または同化促進のための剤(以下、本発明の剤ともいう。)によれば、人体におけるタンパク質の異化の軽減または同化の促進によって、透析患者などの栄養障害またはその可能性のある者における筋肉の減少を抑制または予防することができる。 According to the agent for reducing catabolism or promoting anabolism of the present invention (hereinafter also referred to as the agent of the present invention), by reducing protein catabolism or promoting anabolism in the human body, Muscle loss can be suppressed or prevented in potential individuals.
本発明のタンパク質の異化軽減または同化促進のための剤は、エネルギー100kcal当たり、タンパク質の量が0.5〜5g、リンの量が10〜50mg、ナトリウムの量が10〜40mg、カリウムの量が5〜50mgのものである。
これらタンパク質などの量について、以下、詳しく説明する。
タンパク質の量は、本発明の剤のエネルギー100kcal当たり、0.5〜5g、好ましくは1〜5g、より好ましくは2〜4.5g、特に好ましくは3〜4gである。該量が0.5g未満では、摂取者に対して十分な量のタンパク質を与えることが困難である。該量が5gを超えると、摂取者が、透析患者等のタンパク質の摂取量を制限されている者である場合に、タンパク質の量が過大になり、摂取者の腎臓機能等の改善の程度が低くなる可能性がある。The agent for reducing catabolism or promoting anabolism of the protein of the present invention has a protein amount of 0.5 to 5 g, a phosphorus amount of 10 to 50 mg, a sodium amount of 10 to 40 mg, and a potassium amount of 100 kcal of energy. 5 to 50 mg.
The amount of these proteins will be described in detail below.
The amount of protein is 0.5 to 5 g, preferably 1 to 5 g, more preferably 2 to 4.5 g, and particularly preferably 3 to 4 g per 100 kcal of energy of the agent of the present invention. If the amount is less than 0.5 g, it is difficult to give a sufficient amount of protein to the intaker. When the amount exceeds 5 g, when the intake person is a person who is restricted in the intake of protein such as a dialysis patient, the amount of protein becomes excessive, and the degree of improvement of the intake person's kidney function and the like is increased. May be lower.
リン(P)の量は、本発明の剤のエネルギー100kcal当たり、10〜50mg、好ましくは20〜50mg、より好ましくは25〜45mg、特に好ましくは30〜40mgである。該量が10mg未満では、摂取者に対して十分な量のリンを与えることが困難である。該量が50mgを超えると、摂取者が、透析患者等のリンの摂取量を制限されている者である場合に、リンの量が過大になり、摂取者の腎臓機能等の改善の程度が低くなる可能性がある。
ナトリウム(Na)の量は、本発明の剤のエネルギー100kcal当たり、10〜100mg、好ましくは20〜90mg、より好ましくは30〜80mg、特に好ましくは40〜80mgである。該量が10mg未満では、摂取者に対して十分な量のナトリウムを与えることが困難である。該量が100mgを超えると、摂取者が、透析患者等のナトリウムの摂取量を制限されている者である場合に、ナトリウムの量が過大になり、摂取者の腎臓機能等の改善の程度が低くなる可能性がある。The amount of phosphorus (P) is 10 to 50 mg, preferably 20 to 50 mg, more preferably 25 to 45 mg, particularly preferably 30 to 40 mg per 100 kcal of energy of the agent of the present invention. If the amount is less than 10 mg, it is difficult to give a sufficient amount of phosphorus to the intaker. When the amount exceeds 50 mg, when the intake person is a person whose intake of phosphorus is restricted, such as a dialysis patient, the amount of phosphorus becomes excessive, and the degree of improvement in the kidney function and the like of the intake person is increased. May be lower.
The amount of sodium (Na) is 10 to 100 mg, preferably 20 to 90 mg, more preferably 30 to 80 mg, particularly preferably 40 to 80 mg per 100 kcal of energy of the agent of the present invention. If the amount is less than 10 mg, it is difficult to give a sufficient amount of sodium to the intaker. When the amount exceeds 100 mg, when the intake person is a person whose intake of sodium is restricted, such as a dialysis patient, the amount of sodium becomes excessive, and the degree of improvement in the kidney function and the like of the intake person is reduced. May be lower.
カリウム(K)の量は、本発明の剤のエネルギー100kcal当たり、5〜50mg、好ましくは10〜45mg、より好ましくは15〜40mg、特に好ましくは20〜40mgである。該量が5mg未満では、摂取者に対して十分な量のカリウムを与えることが困難である。該量が100mgを超えると、摂取者が、透析患者等のカリウムの摂取量を制限されている者である場合に、カリウムの量が過大になり、摂取者の腎臓機能等の改善の程度が低くなる可能性がある。
本発明においては、エネルギー100kcal当たりのタンパク質、リン、ナトリウム、カリウムの各量が上述の範囲内であることによって、タンパク質の異化軽減または同化促進の効果を得ることができる。The amount of potassium (K) is 5 to 50 mg, preferably 10 to 45 mg, more preferably 15 to 40 mg, and particularly preferably 20 to 40 mg per 100 kcal of energy of the agent of the present invention. If the amount is less than 5 mg, it is difficult to give a sufficient amount of potassium to the intaker. When the amount exceeds 100 mg, when the intake person is a person whose intake of potassium is restricted, such as a dialysis patient, the amount of potassium becomes excessive, and the degree of improvement in the kidney function and the like of the intake person is reduced. May be lower.
In the present invention, when the amounts of protein, phosphorus, sodium and potassium per 100 kcal of energy are within the above-mentioned ranges, the effect of reducing catabolism or promoting anabolism can be obtained.
本発明の剤は、タンパク質、リン、ナトリウムおよびカリウムに加えて、脂質、糖質、他のミネラル(リン、ナトリウム、カリウム以外のもの)、ビタミンおよび水を含むことができる。この場合、本発明の剤は、水を含むため、流動食として経口摂取することができる。
脂質の好ましい例としては、中鎖脂肪酸トリグリセライドなどが挙げられる。
脂質の量は、本発明の剤のエネルギー100kcal当たり、好ましくは1〜5g、より好ましくは1.5〜4.5g、特に好ましくは2〜4gである。該量が1g未満では、摂取者に対して十分な量の脂質を与えることが困難である。該量が5gを超えると、脂質の量が過大になり、摂取者に必要な栄養のバランスが悪くなることがある。
糖質の好ましい例としては、可溶性多糖類(例えば、デキストリン、オリゴ糖など)が挙げられる。
糖質の量は、本発明の剤のエネルギー100kcal当たり、好ましくは10〜20g、より好ましくは12〜18g、特に好ましくは14〜17gである。該量が10g未満では、摂取者に対して十分な量の糖質を与えることが困難である。該量が20gを超えると、糖質の量が過大になり、摂取者に必要な栄養のバランスが悪くなることがある。The agent of the present invention can contain lipids, carbohydrates, other minerals (other than phosphorus, sodium and potassium), vitamins and water in addition to proteins, phosphorus, sodium and potassium. In this case, since the agent of the present invention contains water, it can be taken orally as a liquid food.
Preferable examples of lipids include medium chain fatty acid triglycerides.
The amount of lipid is preferably 1 to 5 g, more preferably 1.5 to 4.5 g, and particularly preferably 2 to 4 g per 100 kcal of energy of the agent of the present invention. If the amount is less than 1 g, it is difficult to give a sufficient amount of lipid to the intaker. When the amount exceeds 5 g, the amount of lipid becomes excessive, and the nutritional balance necessary for the intake person may be deteriorated.
Preferable examples of the saccharide include soluble polysaccharides (eg, dextrin, oligosaccharide, etc.).
The amount of the saccharide is preferably 10 to 20 g, more preferably 12 to 18 g, and particularly preferably 14 to 17 g per 100 kcal of energy of the agent of the present invention. If the amount is less than 10 g, it is difficult to give a sufficient amount of carbohydrates to the intake person. If the amount exceeds 20 g, the amount of carbohydrates may become excessive, and the nutritional balance necessary for the intake person may be deteriorated.
他のミネラル(リン、ナトリウム、カリウム以外のもの)としては、カルシウム、マグネシウム、鉄、亜鉛等が挙げられる。
カルシウム(Ca)の量は、本発明の剤のエネルギー100kcal当たり、好ましくは10〜50mg、より好ましくは15〜45mg、特に好ましくは20〜40mgである。該量が10mg未満では、摂取者に対して十分な量のカルシウムを与えることが困難である。該量が50mgを超えると、カルシウムの量が過大になり、摂取者に必要な栄養のバランスが悪くなることがある。
マグネシウム(Mg)の量は、本発明の剤のエネルギー100kcal当たり、好ましくは5〜30mg、より好ましくは5〜25mg、特に好ましくは10〜20mgである。該量が5mg未満では、摂取者に対して十分な量のマグネシウムを与えることが困難である。該量が30mgを超えると、マグネシウムの量が過大になり、摂取者に必要な栄養のバランスが悪くなることがあるばかりか、マグネシウムの摂取量が制限される腎不全患者等にとって、腎臓機能等の改善の程度が低くなる可能性がある。Examples of other minerals (other than phosphorus, sodium, and potassium) include calcium, magnesium, iron, and zinc.
The amount of calcium (Ca) is preferably 10 to 50 mg, more preferably 15 to 45 mg, and particularly preferably 20 to 40 mg per 100 kcal of energy of the agent of the present invention. If the amount is less than 10 mg, it is difficult to give a sufficient amount of calcium to the intaker. When the amount exceeds 50 mg, the amount of calcium becomes excessive, and the nutritional balance necessary for the intake person may be deteriorated.
The amount of magnesium (Mg) is preferably 5 to 30 mg, more preferably 5 to 25 mg, and particularly preferably 10 to 20 mg per 100 kcal of energy of the agent of the present invention. If the amount is less than 5 mg, it is difficult to give a sufficient amount of magnesium to the intaker. If the amount exceeds 30 mg, the amount of magnesium becomes excessive, and the nutritional balance necessary for the intakeer may be deteriorated. The degree of improvement may be low.
鉄(Fe)の量は、本発明の剤のエネルギー100kcal当たり、好ましくは0.2〜2mg、より好ましくは0.4〜1.5mg、特に好ましくは0.6〜1.2mgである。該量が0.2mg未満では、摂取者に対して十分な量の鉄分を与えることが困難である。該量が2mgを超えると、鉄分の量が過大になり、摂取者に必要な栄養のバランスが悪くなることがある。
亜鉛の量は、本発明の剤のエネルギー100kcal当たり、好ましくは0.2〜2mg、より好ましくは0.3〜1.5mg、特に好ましくは0.5〜1.2mgである。該量が0.2mg未満では、摂取者に対して十分な量の亜鉛を与えることが困難である。該量が2mgを超えると、亜鉛の量が過大になり、摂取者に必要な栄養のバランスが悪くなることがある。The amount of iron (Fe) is preferably 0.2 to 2 mg, more preferably 0.4 to 1.5 mg, and particularly preferably 0.6 to 1.2 mg per 100 kcal of energy of the agent of the present invention. If the amount is less than 0.2 mg, it is difficult to give a sufficient amount of iron to the intaker. If the amount exceeds 2 mg, the amount of iron may be excessive, and the nutritional balance necessary for the intake person may be deteriorated.
The amount of zinc is preferably 0.2 to 2 mg, more preferably 0.3 to 1.5 mg, particularly preferably 0.5 to 1.2 mg per 100 kcal of energy of the agent of the present invention. When the amount is less than 0.2 mg, it is difficult to give a sufficient amount of zinc to the intaker. When the amount exceeds 2 mg, the amount of zinc becomes excessive, and the nutritional balance necessary for the intake person may be deteriorated.
ビタミンとしては、ビタミンA、ビタミンD、ビタミンE、ビタミンB1、ビタミンB2、ビタミンC等が挙げられる。
ビタミンAの量は、本発明の剤のエネルギー100kcal当たり、好ましくは10〜100μgRE(レチノール当量)、より好ましくは20〜80μgRE、特に好ましくは40〜80μgREである。該量が10μgRE未満では、摂取者に対して十分な量のビタミンAを与えることが困難である。該量が100μgREを超えると、ビタミンAの摂取量が制限される腎不全患者等にとって、腎臓機能等の改善の程度が低くなる可能性がある。
ビタミンDの量は、本発明の剤のエネルギー100kcal当たり、好ましくは0.05〜0.5μg、より好ましくは0.05〜0.3μg、特に好ましくは0.1〜0.2μgである。該量が0.05μg未満では、摂取者に対して十分な量のビタミンDを与えることが困難である。該量が0.5μgを超えると、ビタミンDの摂取量が制限される腎不全患者等にとって、腎臓機能等の改善の程度が低くなる可能性がある。Examples of vitamins include vitamin A, vitamin D, vitamin E, vitamin B1, vitamin B2, and vitamin C.
The amount of vitamin A is preferably 10 to 100 μg RE (retinol equivalent), more preferably 20 to 80 μg RE, particularly preferably 40 to 80 μg RE per 100 kcal of energy of the agent of the present invention. If the amount is less than 10 μg RE, it is difficult to give a sufficient amount of vitamin A to the intaker. When the amount exceeds 100 μg RE, there is a possibility that the degree of improvement in kidney function or the like may be reduced for patients with renal insufficiency and the like in which vitamin A intake is limited.
The amount of vitamin D is preferably 0.05 to 0.5 μg, more preferably 0.05 to 0.3 μg, and particularly preferably 0.1 to 0.2 μg per 100 kcal of energy of the agent of the present invention. When the amount is less than 0.05 μg, it is difficult to give a sufficient amount of vitamin D to the intaker. When the amount exceeds 0.5 μg, there is a possibility that the degree of improvement in kidney function and the like is low for renal failure patients and the like whose vitamin D intake is limited.
ビタミンE、ビタミンB1、ビタミンB2、ビタミンC等は、人体に必要な通常の量を参考にして、適宜、配合すればよい。
ビタミンEの量は、本発明の剤のエネルギー100kcal当たり、通常、0.5〜2mgである。
ビタミンB1の量は、本発明の剤のエネルギー100kcal当たり、通常、0.05〜0.2mgである。
ビタミンB2の量は、本発明の剤のエネルギー100kcal当たり、通常、0.05〜0.2mgである。
ビタミンCの量は、本発明の剤のエネルギー100kcal当たり、通常、2〜10mgである。
本発明においては、固形分を構成する成分として、必要に応じて、食物繊維、甘味料(例えば、パラチノースなど)、乳化剤などをさらに配合することができる。Vitamin E, vitamin B1, vitamin B2, vitamin C and the like may be appropriately blended with reference to normal amounts necessary for the human body.
The amount of vitamin E is usually 0.5 to 2 mg per 100 kcal of energy of the agent of the present invention.
The amount of vitamin B1 is usually 0.05 to 0.2 mg per 100 kcal of energy of the agent of the present invention.
The amount of vitamin B2 is usually 0.05 to 0.2 mg per 100 kcal of energy of the agent of the present invention.
The amount of vitamin C is usually 2 to 10 mg per 100 kcal of energy of the agent of the present invention.
In the present invention, dietary fibers, sweeteners (for example, palatinose, etc.), emulsifiers, and the like can be further blended as components constituting the solid content, if necessary.
水の量は、本発明の剤の容量1ミリリットル当たりのエネルギーが、好ましくは1〜2kcal、より好ましくは1.2〜1.9kcal、特に好ましくは1.4〜1.8kcalになるような量である。該値が1kcal未満では、水分の摂取量が制限される腎不全患者等にとって、腎臓の負担が大きくなり、病状の改善のために好ましくないことがある。該値が2kcalを超えると、水分の摂取量が制限される腎不全患者等にとっても、水分の量が過小になり、身体機能を良好に維持することが困難になる可能性がある。 The amount of water is such that the energy per milliliter of the agent of the present invention is preferably 1 to 2 kcal, more preferably 1.2 to 1.9 kcal, particularly preferably 1.4 to 1.8 kcal. It is. If the value is less than 1 kcal, the burden on the kidney is increased for patients with renal insufficiency, etc., whose water intake is limited, which may be undesirable for improving the medical condition. If the value exceeds 2 kcal, the amount of water may be too small for a renal failure patient or the like whose water intake is limited, and it may be difficult to maintain good physical function.
本発明の好ましい実施形態の一例として、タンパク質、脂質、糖質、ミネラルおよび水を含む剤であって、該剤のエネルギー100kcal当たり、タンパク質の量が0.5〜5g、脂質の量が1〜5g、糖質の量が10〜20g、リンの量が10〜50mg、ナトリウムの量が10〜100mg、カリウムの量が5〜50mgであり、1ミリリットル当たりのエネルギーが1〜2kcalである剤が挙げられる。
この例において、該剤のエネルギー100kcal当たり、カルシウムの量が10〜50mg、マグネシウムの量が5〜30mg、鉄の量が0.2〜2mg、亜鉛の量が0.2〜2mg、ビタミンAの量が10〜100μgRE、ビタミンDの量が0.1〜0.5μgであるものが、より好ましい。
これらの好ましい実施形態例によれば、タンパク質の異化軽減または同化促進の効果を、より高めることができる。As an example of a preferred embodiment of the present invention, an agent comprising protein, lipid, carbohydrate, mineral and water, the amount of protein is 0.5 to 5 g and the amount of lipid is 1 to 1 per 100 kcal of energy of the agent. 5 g, 10 to 20 g of carbohydrate, 10 to 50 mg of phosphorus, 10 to 100 mg of sodium, 5 to 50 mg of potassium, and 1 to 2 kcal of energy per milliliter Can be mentioned.
In this example, per 100 kcal of energy of the agent, the amount of calcium is 10 to 50 mg, the amount of magnesium is 5 to 30 mg, the amount of iron is 0.2 to 2 mg, the amount of zinc is 0.2 to 2 mg, and vitamin A More preferably, the amount is 10 to 100 μg RE and the amount of vitamin D is 0.1 to 0.5 μg.
According to these preferred embodiments, the effect of reducing protein catabolism or promoting anabolism can be further enhanced.
本発明の剤の1回投与分の容量(1回の投与毎の用量)は、好ましくは100〜300ミリリットル、より好ましくは100〜250ミリリットル、さらに好ましくは100〜200ミリリットル、特に好ましくは100〜150ミリリットル、最も好ましくは120〜130ミリリットルである。該値が100ミリリットル未満では、水分の摂取量が制限される腎不全患者等にとっても、水分の量が過小になり、身体機能を良好に維持することが困難になる可能性がある。該値が300ミリリットルを超えると、水分の摂取量が制限される腎不全患者等にとって、腎臓の負担が大きくなり、病状の改善のために好ましくないことがある。
本発明の剤は、透析患者のために好ましく使用される。The volume of one dose of the agent of the present invention (dose for each administration) is preferably 100 to 300 ml, more preferably 100 to 250 ml, further preferably 100 to 200 ml, particularly preferably 100 to 300 ml. 150 milliliters, most preferably 120-130 milliliters. If the value is less than 100 milliliters, the amount of water may be too small for a renal failure patient or the like whose water intake is limited, and it may be difficult to maintain good physical function. When the value exceeds 300 milliliters, the kidney burden increases for patients with renal insufficiency and the like whose water intake is limited, which may be undesirable for improving the medical condition.
The agent of the present invention is preferably used for dialysis patients.
本発明の剤は、該剤の摂取時から3時間後の動脈血中のアミノ酸濃度の値から、非摂取状態における動脈血中のアミノ酸濃度の値を差し引いて得られる値が、0以上になる者に経口投与するための剤として使用することが好ましい。
本発明の剤の使用の要否を定めるための方法として、該剤の摂取時から所定時間後(例えば、1〜5時間後)の動脈血中のアミノ酸濃度の値から、非摂取状態における動脈血中のアミノ酸濃度の値を差し引いて得られる値を求め、該値が0以上であれば、本発明の剤を使用し、該値が0未満(マイナス)であれば、本発明の剤を使用しないと決定する方法が挙げられる。The agent of the present invention is for those whose value obtained by subtracting the value of amino acid concentration in arterial blood in a non-ingested state from the value of amino acid concentration in arterial blood 3 hours after the ingestion of the agent becomes 0 or more It is preferably used as an agent for oral administration.
As a method for determining the necessity of use of the agent of the present invention, from the value of the amino acid concentration in arterial blood after a predetermined time (for example, 1 to 5 hours) after the intake of the agent, The value obtained by subtracting the value of the amino acid concentration is determined. If the value is 0 or more, the agent of the present invention is used. If the value is less than 0 (minus), the agent of the present invention is not used. The method of determining is mentioned.
本発明の剤は、タンパク質の異化軽減または同化促進のための剤として使用することができ、具体的には、透析患者などの栄養障害またはその可能性のある者における筋肉の減少の抑制または予防のための剤として使用することができる。なお、本発明の剤は、タンパク質の異化軽減または同化促進のための治療目的ではない剤として使用することもでき、具体的には、透析患者などの栄養障害またはその可能性のある者における筋肉の減少の抑制または予防のための治療目的ではない剤として使用することもできる。 The agent of the present invention can be used as an agent for reducing protein catabolism or promoting anabolism. Specifically, it suppresses or prevents muscle loss in a nutritional disorder such as a dialysis patient or a person who has the possibility of it. Can be used as an agent for. The agent of the present invention can also be used as an agent that is not a therapeutic purpose for reducing protein catabolism or promoting anabolism. Specifically, it is a muscle disorder in a person having or possibly having a nutritional disorder such as a dialysis patient. It can also be used as a non-therapeutic agent for the suppression or prevention of the decrease in blood pressure.
以下、実施例によって、本発明を説明する。ただし、本発明は、以下の実施例に限定されるものではなく、特許請求の範囲に包含される限りにおいて、種々の実施形態を採ることができる。 Hereinafter, the present invention will be described by way of examples. However, the present invention is not limited to the following examples, and various embodiments can be adopted as long as they are included in the scope of the claims.
[被験者による本発明の剤の摂取および採血]
透析患者の10名を被験者として、以下の実験を行った。
被験者が朝食を摂取した後に来院し、本発明の剤に該当する「明治リーナレンMP」(商品名;株式会社 明治 製)を1本で摂取してから、3時間の透析を受けた。この3時間の透析を終了した時に、被験者から静脈血と動脈血を採血した。
別の週に、被験者が朝食を摂取した後に来院し、「明治リーナレンMP」を摂取せずに、3時間の透析を受けた。この3時間の透析を終了した時に、被験者から静脈血と動脈血を採血した。[Intake and blood collection of the agent of the present invention by a subject]
The following experiment was conducted with 10 dialysis patients as subjects.
After the subject ingested breakfast, he visited the hospital and ingested “Meiji Linalen MP” (trade name; manufactured by Meiji Co., Ltd.) corresponding to the agent of the present invention with one bottle, and then received dialysis for 3 hours. When the dialysis for 3 hours was completed, venous blood and arterial blood were collected from the subjects.
In another week, the subject visited the hospital after eating breakfast and received 3 hours of dialysis without taking "Meiji Linalen MP". When the dialysis for 3 hours was completed, venous blood and arterial blood were collected from the subjects.
「明治リーナレンMP」の1本当たりの容量、エネルギーおよび主な成分は、次のとおりである。
(1)容量:125ミリリットル
(2)エネルギー:200kcal
(3)主な成分および含有量
タンパク質(乳タンパク質):7.0g
脂質(中鎖脂肪酸トリグリセライドなど):5.6g
糖質(デキストリン):29.8g
ナトリウム:120mg
カリウム:60mg
カルシウム:60mg
マグネシウム:30mg
リン:70mg
鉄:1.76mg
亜鉛:1.50mg
塩素:20mg
ビタミンA:120μgRE
ビタミンD:0.26μg
ビタミンE:2.0mg
ビタミンB1:0.20mg
ビタミンB2:0.24mg
ビタミンB6:1.26mg
ビタミンC:10.0mg
食物繊維:2.0g
水分:94.4gThe capacity, energy, and main components per bottle of “Meiji Linalen MP” are as follows.
(1) Capacity: 125ml (2) Energy: 200kcal
(3) Main components and contents Protein (milk protein): 7.0 g
Lipid (Medium chain fatty acid triglyceride, etc.): 5.6 g
Carbohydrate (dextrin): 29.8g
Sodium: 120mg
Potassium: 60mg
Calcium: 60mg
Magnesium: 30mg
Phosphorus: 70mg
Iron: 1.76 mg
Zinc: 1.50mg
Chlorine: 20mg
Vitamin A: 120 μg RE
Vitamin D: 0.26 μg
Vitamin E: 2.0mg
Vitamin B1: 0.20mg
Vitamin B2: 0.24mg
Vitamin B6: 1.26mg
Vitamin C: 10.0mg
Dietary fiber: 2.0g
Moisture: 94.4g
[採血した血液試料についてのアミノ酸濃度の測定]
採血した血液試料のアミノ酸濃度は、以下の方法によって測定した。
採血した後に、常法にしたがって、血液試料から血漿を分離し、この血漿を、EDTA二ナトリウムを収容した容器に入れ、測定時まで凍結保存した。測定時に容器内の内容物を解凍し、解凍後の内容物を0.5ミリリットルの容量だけ採り、除タンパク処理した後に、遠心分離処理(12,000rpm、10分間)を2回で繰り返した。上清を分取し、この上清に反応試薬(商品名:アミノタグ ワコー アミノ酸自動分析用、和光純薬工業株式会社製)を加えて、混合および加温し、目的成分である遊離アミノ酸を誘導体化した。その後、誘導体化した遊離アミノ酸を、高速液体クロマトグラフィー質量分析計(商品名:LCMS2020、株式会社島津製作所製)を用いて分析し、血液試料のアミノ酸濃度(25種類)を得た。この際、液体クロマトグラフィーのカラムとして、「イナートシル ODS−3」(商品名;寸法:φ2.1×100mm、ジーエルサイエンス株式会社製)を用いた。[Measurement of amino acid concentration in collected blood samples]
The amino acid concentration of the collected blood sample was measured by the following method.
After blood collection, plasma was separated from the blood sample according to a conventional method, and this plasma was placed in a container containing EDTA disodium and stored frozen until measurement. At the time of measurement, the contents in the container were thawed, and after the thawed contents were taken in a volume of 0.5 ml and subjected to protein removal treatment, centrifugation (12,000 rpm, 10 minutes) was repeated twice. The supernatant is collected, and a reaction reagent (trade name: Aminotag Wako for automatic amino acid analysis, manufactured by Wako Pure Chemical Industries, Ltd.) is added to the supernatant, mixed and heated, and the free amino acid as the target component is derived. Turned into. Thereafter, the derivatized free amino acid was analyzed using a high performance liquid chromatography mass spectrometer (trade name: LCMS2020, manufactured by Shimadzu Corporation) to obtain amino acid concentrations (25 types) of the blood sample. At this time, “Inertosyl ODS-3” (trade name; dimensions: φ2.1 × 100 mm, manufactured by GL Sciences Inc.) was used as a column for liquid chromatography.
[数値a〜dの算出]
採血した血液試料のアミノ酸濃度に基いて、次の式から、数値a〜dを求めた。
数値a=「本発明の剤を摂取した場合の動脈血中の各アミノ酸の濃度」−「本発明の剤を摂取しない場合の動脈血中の各アミノ酸の濃度」
数値b=「本発明の剤を摂取した場合の静脈血中の各アミノ酸の濃度」−「本発明の剤を摂取した場合の動脈血中の各アミノ酸の濃度」
数値c=「本発明の剤を摂取しない場合の静脈血中の各アミノ酸の濃度」−「本発明の剤を摂取しない場合の動脈血中の各アミノ酸の濃度」
数値d=数値b−数値c[Calculation of numerical values a to d]
Based on the amino acid concentration of the collected blood sample, numerical values a to d were obtained from the following equations.
Numerical value a = “concentration of each amino acid in arterial blood when taking the agent of the present invention” − “concentration of each amino acid in arterial blood when not taking the agent of the present invention”
Numerical value b = “concentration of each amino acid in venous blood when the agent of the present invention is ingested” − “concentration of each amino acid in arterial blood when the agent of the present invention is ingested”
Numerical value c = “concentration of each amino acid in venous blood when not taking the agent of the present invention” − “concentration of each amino acid in arterial blood when not taking the agent of the present invention”
Numerical value d = Numerical value b−Numerical value c
数値aは、本発明の剤の投与による動脈血中の各アミノ酸の濃度の上昇の幅を示し、タンパク質の同化の促進を示唆する数値である。
数値bおよび数値cは、本発明の剤を摂取した場合(数値b)と摂取しない場合(数値c)の各々におけるタンパク質の異化の程度を示す。これらの数値がプラスであれば、タンパク質の異化が促進されていることを示し、これらの数値がマイナスであれば、タンパク質の同化が促進されている(換言すると、異化が軽減されている)ことを示す。つまり、数値b(本発明の剤を摂取した場合)を例にとると、血液は動脈から静脈へと流れるので、静脈血中のアミノ酸の濃度から、動脈血中のアミノ酸の濃度を差し引いた値が、マイナスであるということは、末梢組織(栄養供給を受ける筋肉)において、タンパク質の同化(アミノ酸からの合成)が促進されていることを示す。逆に、静脈血中のアミノ酸の濃度から、動脈血中のアミノ酸の濃度を差し引いた値が、プラスであるということは、末梢組織(栄養供給を受ける筋肉)において、タンパク質の異化(アミノ酸への分解)が促進されていることを示す。
数値dは、マイナスであれば、本発明の剤の摂取によって、タンパク質の異化の軽減(同化の促進)が生じていることを示す。The numerical value a indicates the range of increase in the concentration of each amino acid in arterial blood by administration of the agent of the present invention, and is a numerical value that suggests promotion of protein assimilation.
The numerical value b and the numerical value c indicate the degree of protein catabolism when the agent of the present invention is ingested (numerical value b) and when not ingested (numerical value c). A positive value indicates that protein catabolism is promoted, and a negative value indicates that protein assimilation is promoted (in other words, catabolism is reduced). Indicates. That is, taking the numerical value b (when the agent of the present invention is taken) as an example, blood flows from the artery to the vein, so the value obtained by subtracting the amino acid concentration in the arterial blood from the amino acid concentration in the venous blood is The negative value indicates that protein assimilation (synthesis from amino acids) is promoted in peripheral tissues (muscles receiving nutrient supply). Conversely, if the value obtained by subtracting the amino acid concentration in arterial blood from the concentration of amino acid in venous blood is positive, protein catabolism (degradation into amino acids) in peripheral tissues (muscles that receive nutrition) ) Is promoted.
If the numerical value d is negative, it indicates that reduction of protein catabolism (promotion of assimilation) occurs due to the intake of the agent of the present invention.
[数値dと度数の関係]
被験者の数(10名)とアミノ酸の種類(25種類)の組み合わせは、250である。これら250の組み合わせの各々を、1つの度数として扱う。測定操作上の問題(検出感度以下)のため測定値を得ることのできなかった6つの度数を除く244の度数について、(a)すべての数値aを対象にした場合(数値aがマイナスであるかなどを問わない場合;244度数)の数値d、(b)数値aが0未満(マイナス)である場合の数値d、(c)数値aが0以上である場合の数値d、の各場合について、数値dを、10の幅を有する区分毎に分類して、これらの区分に含まれる度数を調べた。結果を表1に示す。[Relationship between numerical value d and frequency]
The combination of the number of subjects (10 persons) and amino acid types (25 types) is 250. Each of these 250 combinations is treated as one frequency. Regarding the 244 frequencies excluding the 6 frequencies for which measurement values could not be obtained due to measurement operational problems (below detection sensitivity), (a) when all numerical values a are targeted (the numerical value a is negative) Whether or not; 244 degrees) numerical value d, (b) numerical value d when numerical value a is less than 0 (minus), (c) numerical value d when numerical value a is 0 or more The numerical value d was classified into sections having a width of 10, and the frequencies contained in these sections were examined. The results are shown in Table 1.
表1中、数値aが0未満(マイナス)の場合で、数値dが0未満(マイナス)の区分に含まれる度数の合計は、32であり(表1のAの部分)、全体(112)中の割合として28.6%である。また、数値aが0未満の場合で、数値dが0以上の区分に含まれる度数の合計は、80であり(表1のBの部分)、全体(112)中の割合として71.4%である。
数値aが0以上の場合で、数値dが0未満(マイナス)の区分に含まれる度数の合計は、61であり(表1のCの部分)、全体(132)中の割合として46.2%である。また、数値aが0以上の場合で、数値dが0以上の区分に含まれる度数の合計は、71であり(表1のDの部分)、全体(132)中の割合として53.8%である。In Table 1, when the numerical value a is less than 0 (minus) and the numerical value d is less than 0 (minus), the total number of frequencies included is 32 (part A in Table 1), and the whole (112) The ratio is 28.6%. In addition, when the numerical value a is less than 0, the total number of frequencies included in the category in which the numerical value d is 0 or more is 80 (part B in Table 1), and 71.4% as a ratio in the whole (112) It is.
In the case where the numerical value a is 0 or more and the numerical value d is less than 0 (minus), the total number of frequencies is 61 (part C in Table 1), and 46.2 as a ratio in the whole (132). %. In addition, in the case where the numerical value a is 0 or more, the total number of frequencies included in the category where the numerical value d is 0 or more is 71 (part D in Table 1), and 53.8% as a percentage in the whole (132) It is.
数値aが0未満(マイナス)の場合と、数値aが0以上の場合とで、このように数値dの分布が異なることについて、次のように考察することができる。
本発明の剤を摂取しない場合に比べて、本発明の剤を摂取した場合のほうが、動脈血中のアミノ酸の濃度が高い(換言すると、数値aがプラスである)または同等(換言すると、数値aが0である)という結果を得た被験者にとっては、本発明の剤の摂取は、タンパク質の異化の軽減(換言すると、数値dがマイナスになること)を示す頻度(可能性)を、50%近く(46.2%)まで高める。It can be considered as follows that the distribution of the numerical value d is different between the case where the numerical value a is less than 0 (minus) and the case where the numerical value a is 0 or more.
Compared to the case where the agent of the present invention is not taken, the concentration of amino acids in arterial blood is higher when the agent of the present invention is taken (in other words, the numerical value a is positive) or equivalent (in other words, the numerical value a For a subject who has obtained a result of 0), the intake of the agent of the present invention has a frequency (possibility) showing a reduction in protein catabolism (in other words, the numerical value d becomes negative) by 50%. Increase to close (46.2%).
一方、本発明の剤を摂取しない場合に比べて、本発明の剤を摂取した場合のほうが、動脈血中のアミノ酸の濃度が低い(換言すると、数値aがマイナスである)という結果を得た被験者にとっては、本発明の剤を摂取しても、タンパク質の異化の軽減(換言すると、数値dがマイナスになること)を示す頻度(可能性)は、28.6%であり、低い。
統計学的にも、数値aによる層別化(0を境にした2区分化)と、タンパク質の異化の軽減の効果(数値dがマイナスであるか否か)の間には、有意な関連があった(mxn分割表の検定:p=0.0183)。On the other hand, the subject who obtained the result that the concentration of amino acids in arterial blood was lower (in other words, the numerical value a was negative) when the agent of the present invention was ingested than when the agent of the present invention was not ingested. Therefore, even when the agent of the present invention is ingested, the frequency (possibility) showing reduction of protein catabolism (in other words, the numerical value d becomes negative) is as low as 28.6%.
Statistically, there is also a significant relationship between stratification by numerical value a (two-partitioning with 0 as a boundary) and the effect of reducing protein catabolism (whether numerical value d is negative). (Mxn contingency table test: p = 0.0183).
したがって、本発明の剤は、該剤の摂取時から3時間後の動脈血中のアミノ酸濃度の値から、非摂取状態における動脈血中のアミノ酸濃度の値を差し引いて得られる値が、0以上になる者に経口投与する場合に、特にタンパク質の異化軽減または同化促進の優れた効果が得られることが、実際の透析患者での試験により充分に確認された。 Therefore, in the agent of the present invention, the value obtained by subtracting the value of the amino acid concentration in arterial blood in a non-ingested state from the value of the amino acid concentration in arterial blood 3 hours after the ingestion of the agent becomes 0 or more. In the case of oral administration to a person, it has been fully confirmed by an actual dialysis patient test that an excellent effect of reducing catabolism or promoting anabolism can be obtained.
以上より、本発明の剤は、タンパク質の異化軽減または同化促進の優れた効果を持つことが確認された。本発明の剤は、食品として十分に摂取経験のある成分で構成されており、医薬品のみならず、食品としても提供できる。これにより、タンパク質の異化軽減または同化促進作用に基づいた、腎不全等の腎疾患を予防する作用を有する医薬品や食品を提供することもできる。 From the above, it was confirmed that the agent of the present invention has an excellent effect of reducing protein catabolism or promoting anabolism. The agent of the present invention is composed of ingredients that have been sufficiently ingested as food, and can be provided not only as a pharmaceutical product but also as a food product. Thereby, the pharmaceutical and foodstuff which have the effect | action which prevents renal diseases, such as a renal failure based on the catabolism reduction | restoration or assimilation promotion effect | action, can also be provided.
Claims (6)
エネルギー100kcal当たり、タンパク質の量が0.5〜5g、脂質の量が1〜5g、糖質の量が10〜20g、リンの量が10〜50mg、ナトリウムの量が10〜100mg、カリウムの量が5〜50mgであり、
1ミリリットル当たりのエネルギーが1〜2kcalであることを特徴とするタンパク質の異化軽減または同化促進のための剤。An agent for reducing catabolism or promoting anabolism of protein, which can be ingested as a liquid food, including protein, lipid, carbohydrate, mineral and water,
Per 100 kcal of energy, the amount of protein is 0.5-5 g, the amount of lipid is 1-5 g, the amount of carbohydrate is 10-20 g, the amount of phosphorus is 10-50 mg, the amount of sodium is 10-100 mg, the amount of potassium Is 5 to 50 mg,
An agent for reducing protein catabolism or promoting anabolism, wherein the energy per milliliter is 1 to 2 kcal.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013190099 | 2013-09-13 | ||
JP2013190099 | 2013-09-13 | ||
PCT/JP2014/074051 WO2015037655A1 (en) | 2013-09-13 | 2014-09-11 | Agent for reducing catabolism or promoting assimilation of protein |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2015037655A1 true JPWO2015037655A1 (en) | 2017-03-02 |
JP6749097B2 JP6749097B2 (en) | 2020-09-02 |
Family
ID=52665755
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015536619A Active JP6749097B2 (en) | 2013-09-13 | 2014-09-11 | Agents for reducing or catabolizing protein catabolism |
Country Status (5)
Country | Link |
---|---|
JP (1) | JP6749097B2 (en) |
CN (1) | CN105530947A (en) |
HK (1) | HK1217181A1 (en) |
SG (2) | SG11201601734XA (en) |
WO (1) | WO2015037655A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107106684A (en) * | 2015-03-20 | 2017-08-29 | 株式会社明治 | Renal function improver |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH1066541A (en) * | 1996-08-27 | 1998-03-10 | Meiji Milk Prod Co Ltd | Liquid prepared nutrient composition adapted to each symptom of renal disease patient |
WO2010064714A1 (en) * | 2008-12-05 | 2010-06-10 | 味の素株式会社 | Nutrient composition |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7696219B2 (en) * | 2000-09-27 | 2010-04-13 | Everett Laboratories, Inc. | Method and composition for supplementation of nutritional deficiences in renal patients |
JP2008247748A (en) * | 2007-03-29 | 2008-10-16 | En Otsuka Pharmaceutical Co Ltd | Nutritive composition for dialysis patient |
JP2012019691A (en) * | 2010-06-17 | 2012-02-02 | Morinaga Milk Ind Co Ltd | Oral nutrient composition for kidney disease patient |
-
2014
- 2014-09-11 SG SG11201601734XA patent/SG11201601734XA/en unknown
- 2014-09-11 JP JP2015536619A patent/JP6749097B2/en active Active
- 2014-09-11 WO PCT/JP2014/074051 patent/WO2015037655A1/en active Application Filing
- 2014-09-11 CN CN201480050114.5A patent/CN105530947A/en active Pending
- 2014-09-11 SG SG10201801824SA patent/SG10201801824SA/en unknown
-
2016
- 2016-05-08 HK HK16105219.6A patent/HK1217181A1/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH1066541A (en) * | 1996-08-27 | 1998-03-10 | Meiji Milk Prod Co Ltd | Liquid prepared nutrient composition adapted to each symptom of renal disease patient |
WO2010064714A1 (en) * | 2008-12-05 | 2010-06-10 | 味の素株式会社 | Nutrient composition |
Non-Patent Citations (4)
Title |
---|
化学と生物, vol. 45, no. 3, JPN7018001873, 2007, pages 203 - 210, ISSN: 0003811997 * |
日本透析医学界雑誌, vol. Vol.38、Supplement 1, JPN6018021050, 2005, pages 1040 - 4179, ISSN: 0004107975 * |
松井: "浮腫がある患者の経腸栄養管理", 臨床栄養, vol. 118, no. 3, JPN6014051886, 2011, pages 268 - 272, ISSN: 0003811996 * |
静脈経腸栄養年鑑2011, JPN6018021052, 2011, pages 67 - 107, ISSN: 0004107976 * |
Also Published As
Publication number | Publication date |
---|---|
JP6749097B2 (en) | 2020-09-02 |
HK1217181A1 (en) | 2016-12-30 |
SG11201601734XA (en) | 2016-04-28 |
SG10201801824SA (en) | 2018-04-27 |
CN105530947A (en) | 2016-04-27 |
WO2015037655A1 (en) | 2015-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Sabatino et al. | Protein-energy wasting and nutritional supplementation in patients with end-stage renal disease on hemodialysis | |
Bossola et al. | Malnutrition in hemodialysis patients: what therapy? | |
JP6420156B2 (en) | Use of casein composition | |
CN115350200A (en) | Synthetic compositions for the treatment of metabolic disorders | |
US10987368B2 (en) | Synthetic composition for preventing or treating CVD | |
Fitschen et al. | Efficacy of beta‐hydroxy‐beta‐methylbutyrate supplementation in maintenance hemodialysis patients | |
EP2763683A1 (en) | Treatment of eosinophilic esophagitis | |
US11896613B2 (en) | Functional food | |
Takahira et al. | Randomized, Double-Blind, Controlled, Comparative Trial of Formula Food Containing Soy Protein vs. Milk Protein in Visceral Fat Obesity–FLAVO Study– | |
Paley | Discovery of gut bacteria specific to Alzheimer’s associated diseases is a clue to understanding disease etiology: meta-analysis of population-based data on human gut metagenomics and metabolomics | |
JP2006131512A (en) | Composition for accelerating secretion of adiponectin and food and drink containing the composition | |
WO2004017916A2 (en) | Cardiovascular therapy composition including transfer factor and therapeutic methods including use of the composition | |
Genton et al. | Glycine increases fat‐free mass in malnourished haemodialysis patients: a randomized double‐blind crossover trial | |
Aluko et al. | Honey’s ability to reduce blood pressure and heart rate in healthy male subjects | |
JP6749097B2 (en) | Agents for reducing or catabolizing protein catabolism | |
JP5955236B2 (en) | Blood cresol lowering agent | |
JP5546833B2 (en) | Acetaldehyde / ethanol reducing agent | |
Noce et al. | Uremic Sarcopenia and Its Possible Nutritional Approach. Nutrients 2021, 13, 147 | |
Watanabe et al. | A Cross-Sectional Study on the Effects of Long Term Very Low Protein Diets in Patients with Chronic Kidney Disease Serum and Urine DEXA and Amino Acid Profiles | |
Gabriel et al. | Ingestion of ferrous sulfate increases ferremia in patients with short bowel syndrome | |
Abbas et al. | Relationship between vitamin B12, Homocysteine, and Immunological parameters in patients with type 2 diabetes | |
Andersen et al. | A randomized study of the effect of fish oil on n-3 fatty acid incorporation and nutritional status in lung cancer patients | |
WO2020029221A1 (en) | Composition with inhibiting fat formation and antioxidative activities and use thereof | |
JP2013510126A (en) | Choline-containing pharmaceutical composition | |
Fitschen | Efficacy of beta-hydroxy-beta-methylbutyrate (HMB) supplementation in hemodialysis patients |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20160413 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160413 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170823 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180612 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180726 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181009 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20190312 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190611 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20190724 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20190813 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20190906 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200811 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6749097 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |